Core Scientific Q3 2026: Billable MW Grows, But Customer Diversification Still Missing

What happened

Core Scientific reported Q3 2026 results reflecting continued growth in AI/HPC colocation, with billable customer power capacity expanding toward the 300–350 MW range, up from 225 MW at end of Q1. However, leased customer power capacity showed only modest movement from the 590 MW level, signaling that new customer contracting has been slower than capacity creation. Customer concentration remained a key risk, with the top colocation customer still accounting for over half of total revenue, though management indicated active discussions with multiple prospects. Liquidity remained constrained as the company funded aggressive construction through secured debt, bitcoin sales, and customer prepayments, while utility-required restricted cash and collateral postings continued to rise. The earnings call highlighted management's confidence in the conversion strategy, but the market remains skeptical about the timeline to diversify revenue and reduce merchant capacity risk.

Implication

The Q3 update suggests CORZ is on track with its base-case scenario: billable MW is rising, but leased MW and customer concentration have not improved materially, which leaves the stock exposed to single-customer execution risk. The heavy reliance on secured financing and completion guarantees means any construction delay or cost overrun could quickly erode equity value, especially with $1.47B in near-term contractual commitments. Investors should watch for signs of new large HPC customer signings in the coming quarters; a meaningful jump in leased MW above 650 and a drop in top-customer revenue below 50% would validate the bull case and support a re-rating toward $36+. Conversely, if the next two filings show leased MW stagnant at 590 and restricted cash rising above $150M, the bear case becomes more likely, with downside toward $18. Given the current price near the base-case implied value of $28, the risk/reward is balanced, and a WAIT rating remains appropriate until clearer evidence of diversification emerges.

Thesis delta

The Q3 results confirm the base-case trajectory: billable MW is increasing but leased MW and customer concentration have not yet improved enough to shift the thesis. The investment case now hinges even more on the next two quarters to demonstrate customer diversification; without signed new MW, the liquidity drag from secured debt and restricted cash will increasingly weigh on the equity. The thesis remains WAIT, with conviction slightly lower due to the absence of a diversification catalyst at the call.